Agilent Technologies, Inc. has unveiled its financial performance for the past three fiscal years, with a focus on its Life Sciences and Diagnostics Markets, CrossLab, and Applied Markets segments. The report provides a comprehensive look at the revenue, gross margin, research and development expenses, selling, general and administrative expenses, income from operations, and operating margin for each quarter within the fiscal years 2022, 2023, and 2024.
In the Life Sciences and Diagnostics Markets segment, the company reported a decrease in revenue from $2,780 million in FY23 to $2,466 million in FY24, with a noticeable decline in gross margin from 56.7% to 54.5%. Despite this, the income from operations increased from $673 million to $484 million, with the operating margin decreasing from 24.2% to 19.6% over the same period.
For the CrossLab segment, Agilent Technologies, Inc. experienced a slight increase in revenue from $2,656 million in FY23 to $2,747 million in FY24. The gross margin fluctuated between 55.3% and 56.9%, while the income from operations rose from $839 million to $925 million. The operating margin also varied, starting at 31.6% in FY23 and ending at 33.7% in FY24.
In the Applied Markets segment, revenue dropped from $1,441 million in FY22 to $1,297 million in FY24. The gross margin remained relatively stable, hovering around 55.7%. Income from operations fluctuated throughout the periods, with a noticeable decline from $367 million in FY22 to $312 million in FY24. The operating margin also experienced fluctuations, starting at 25.5% in FY22 and ending at 24.0% in FY24.
The market has reacted to these announcements by moving the company's shares -1.4% to a price of $138.96. Check out the company's full 8-K submission here.
